Table 1

T cell epitopes in genotype-3a infection

ProteinAmino acid3a Peptide sequence used in T cell assaysPatient noPatient viral sequence pre-treatmentHLATreatment outcomeDefining CD4:CD8 T cell subsets
Core27–44GGQIVGGVYVLPRRGPRL362GGQIVGGVYVLPRRGPRLDRB1 0103, 0701SVRNA
73–90GRSWAQPGYPWPLYGNEG* 416GRSWAQPGYPWPLYGNEG
  • DRBI 0101, 0701

  • DQBI 0201, 0501

SVRNA
143–158PVGGVARALAHGVRAL* 110PAGGVARALAHGVRALDRB1 0801, 1101SVRCD4
331PVGGVARALAHGVRALNASVR
437PVGGVARALAHGVRALDRB1 0103, 0501SVR
NS3 helicase1513–1529RPSGMFDSVVL* 140RPSGMFDSVVLCECYDAA2402, A3002, B0702, B3501SVRCD8
235RPSGMFDSVVLCECYDAA0301, A3002, B0702, B3501, C0401, C0702SVR
362RPSGMFDSVVLCECYDAA2402, B3501, B4402, C0401, C0409SVR
NS4b1791–1806PAVASLMAFTASVTSPL* 416PAVASLMAFTASVTSPL
  • A0101, A0201, B0801, B5701, C0602, C0701

  • DRB1 0101, 0701

SVRCD8
437NA
  • A0201, A2601, B3801, B2702, C1203, C0102

  • DRB1 0103, 0101

SVR
1824–1841THLAGPQSSSAFVVSGLA* 437NA
  • A0201, A2601, B3801, B2702, C1203, C0102

  • DRB1 0103, 0101

SVRNA
1918–1933EGAVQWMNRLIAFASR 410EGAVQWMNRLIAFASR
  • A0101, A3001, B1302, B4402, C0602, C0501

  • DRB1 0701, DQB1 0201

NRCD8
NS5a2029–2046GVMSTRCPCGASIAGHVK* 129GVMSTRCPCGASITGHVKA1101, A7401, B4403, B38, C04, C0702RELCD8
NS5b2946–2963GKAKICGLYLFNWAVRTK* 275GKAKITGLYLFNWAVRTK
  • A1101, B0702, B4402, C0501, C0702

  • DRB1 0401, 0407

SVRCD8
2965–2975KLTPLPAAGQL* 450KLTPLPAAGLLNARELCD8
  • Peptide amino acid sequence and patient viral sequence from pre-treatment time point are shown (amino acid differences between these are shown in bold).

  • CD4:CD8 T cell subset analysis was assessed using PBMC in IFN-γ ELISpot assays following CD8 depletion.

  • * Epitopes where viral sequence is different between genotypes-3a and -1.

  • Peptides restricted to 11 residues in ELISpot assays based on previously published epitope or the overlapping sequence between two adjacent immunogenic peptides.

  • Epitopes where viral sequence is identical between genotypes-3a and -1a.

  • IFN, interferon; NA, not available (PCR amplification not possible or insufficient sample); PBMC, peripheral blood mononuclear cells; REL, relapse; SVR, sustained virological response; NR, non-responder.